← boardnext 2026-07-31next 2026-09-28next 2027-02-12next 2027-03
OCGN
Ocugendistress 7/10 · high distress / dilution risk$1.25-3%today-50% from 52w high
Metabolic / Obesity 1Ophthalmology 1
Lead: geographic atrophy secondary to dry age-related macular degeneration · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$32M
Runway
0.5 yrs
Shares 1y
+16%
Price & events
-24.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.1%
1D
-8.8%
1W
-9.4%
1M
-25.1%
3M
-24.7%
6M
+6.8%
1Y
-26.5%
2Y
-82.0%
5Y
-59.3%
All
Overview
- Market Cap
- $423.19M
- Enterprise Value
- $415.48M
- Volume
- 457.24K
- 52 Week Range
- $0.95 – $2.48
- Total Shares
- 338.52M
- Float Shares
- 316.84M
- Short %
- 31.31%
- % Held by Insiders
- 1.68%
- % Held by Institutions
- 34.57%
- RVOL
- 0.06x
- Beta
- 2.18
Pipeline stages · 4 programs
OCU200
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
OCU410ST
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Sub-Retinal Administration of OCU400-301
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-31 Estimated 50% readout ~2026-08-30 | Phase 1 | OCU200 | Center Involved Diabetic Macular Edema, Diabetic Macular Edema | 24 | recruiting |
| 2026-09-28 Estimated 50% readout ~2026-12-12 | Phase 2/3 | OCU410STrare pediatricorphan | Stargardt Disease | — | active not recruiting |
| 2027-02-12 Estimated 50% readout ~2027-04-28 | Phase 3 | Sub-Retinal Administration of OCU400-301 | Retinitis Pigmentosa | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 1/2 | OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dosermatorphan | Retinitis Pigmentosa, Leber Congenital Amaurosis | — | active not recruiting |
| 2026-02-17 | Phase 1/2 | — | Geographic Atrophy | 60 | active not recruiting |
Catalyst news & presentations · 13
- 2028Guided 40%regulatory submissionFiled (NDA/BLA)OCU410 · BLA filing for OCU410SEC 8-K
- second quarter of 2027Guided 70%regulatory submissionFiled (NDA/BLA)OCU400 · Complete BLA submission for OCU400SEC 8-K
- mid-2027Guided 55%regulatory submissionFiled (NDA/BLA)OCU410ST · Plan to submit BLASEC 8-K
- first quarter of 2027Guided 70%readoutPhase 3OCU400 · Topline Phase 3 data expectedSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 3OCU410 · Initiate Phase 3 trialSEC 8-K
- third quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)OCU400 · Rolling BLA submission expected to beginSEC 8-K
- third quarter of 2026Guided 70%trial initiationsecondaryPhase 3OCU410 · Initiate Phase 3 registrational trialSEC 8-K
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-13partnershipOCU400 · Binding term sheet with Roots Pharmaceutical to license OCU400 for retinitis pigmentosa in MENA regionSEC 8-K
- later this quarterreadoutPhase 2OCU410 · Full Phase 2 data readoutSEC 8-K
- 2025-06-01fda agreementOCU410ST · FDA cleared IND amendment to initiate Phase 2/3 pivotal confirmatory trialSEC 8-K
- this yeartrial initiationsecondaryPhase 1OCU500 · NIAID to submit IND for Phase 1 trial of OCU500 COVID-19 vaccineSEC 8-K
- 2024-08-04fda agreementOCU400 · FDA approved expanded access program for retinitis pigmentosaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+814% upside) · 7 analysts
- 2026-05-27Canaccord GenuityBuy
- 2026-03-25HC Wainwright & Co.Buy
- 2026-03-25Chardan CapitalBuy
- 2026-03-17Canaccord GenuityBuy
- 2026-03-11OppenheimerOutperform
- 2026-03-05Chardan CapitalBuy
Competitors — geographic atrophy secondary to dry age-related macular degeneration
- none identified
Recent news
- 2026-07-22Ocugen Inc (OCGN) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
- 2026-07-20Ocugen (OCGN) targets 250M-share authorization increase tied to $130M converts - Stock Titan
- 2026-07-20Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
- 2026-07-17Why Did OCGN Stock Rise Today? - Stocktwits
- 2026-07-16Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
- 2026-07-14Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
- 2026-07-13Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.